News coverage about Johnson & Johnson (NYSE:JNJ) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.857549689986 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Smoking Is Just One Way To Use Marijuana: An Introduction To Vaporizers, Edibles, Oils, Tinctures, Dabs And Other Cannabis Products (finance.yahoo.com)
- Vetr Lowers Johnson & Johnson (JNJ) to Hold (americanbankingnews.com)
- Johnson & Johnson (JNJ) Receives Buy Rating from Royal Bank of Canada (americanbankingnews.com)
- Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Johnson & Johnson Investors (JNJ) (bizjournals.com)
- Johnson & Johnson (JNJ) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
JNJ has been the subject of a number of research reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price for the company in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. Stifel Nicolaus upped their price objective on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Wells Fargo reissued an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $144.43.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same period last year, the firm posted $1.58 EPS. Johnson & Johnson’s revenue for the quarter was up 11.5% on a year-over-year basis. research analysts forecast that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.62%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s payout ratio is currently 46.03%.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.22% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Johnson & Johnson (NYSE:JNJ) Stock Price” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/31/johnson-johnson-jnj-earns-daily-media-impact-score-of-0-16/1983236.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.